Journal: British journal of haematology
This publication reviews advances in the management of myeloma bone disease, a significant cause of morbidity despite improved survival in multiple myeloma patients due to effective immune-mediated therapies.
It highlights the importance of anti-resorptive treatments, such as bisphosphonates, which remain standard care to reduce skeletal-related events.
The article also covers:
- Pathogenesis and diagnosis of bone disease in myeloma
- Emerging strategies targeting osteoblast function
- Effects of anti-myeloma therapies on bone health
- Use of biomarkers to tailor bone-targeted treatment intensity and duration